All In Biotech

Drug Trial Radar · NCT03372057

A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Feb 22, 2018

Primary completion

Dec 22, 2023

Study completion Dec 22, 2023

Sponsor

Lead sponsor
SecuraBioIndustry
Sponsor type
Industry
First posted
Dec 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).

Conditions

  • Peripheral T-cell Lymphoma

Interventions

  • DuvelisibDrug

    Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.

  • DuvelisibDrug

    Duvelisib PO 75 mg BID in 28-day cycles.

  • DuvelisibDrug

    Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano CriteriaTime frame: 56 days (2 cycles; 28-day cycles)
  2. ORR as Assessed by the Independent Review Committee (IRC) Using the Lugano CriteriaTime frame: 56 days (2 cycles; 28-day cycles)

Locations

36 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • University of California - Irvine

    Irvine, California

  • University of California - Los Angeles

    Los Angeles, California

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University - Feinberg School of Medicine

    Chicago, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • University of Maryland

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Stony Brook Cancer Center

    Stony Brook, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Novant Health

    Charlotte, North Carolina

  • Duke University

    Durham, North Carolina

  • The Ohio State University

    Columbia, Ohio

  • Toledo Cancer Center

    Toledo, Ohio

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Baylor Research Institute - Charles Sammons Cancer Center

    Dallas, Texas

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Saxony, Germany

  • Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV

    Halle, Saxony-Anhalt, Germany

  • ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo

    Bergamo, Italy

  • A.O.di Bologna Policl.S.Orsola

    Bologna, Italy

  • Ieo, Irccs

    Milan, Italy

  • Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore

    Roma, Italy

  • Azienda Ospedaliera Santa Maria di Terni

    Terni, Italy

  • Japanese Site 8

    Fukuoka, Japan

  • Japanese Site 5

    Kobe, Japan

  • Japanese Site 3

    Miyagi, Japan

  • Japanese Site 6

    Nagoya, Japan

  • Japanese Site 7

    Niigata, Japan

  • Japanese Site 1

    Okayama, Japan

  • Japanese Site 2

    Tokyo, Japan

  • Japanese Site 4

    Tokyo, Japan

  • Christie Hospital NHS Foundation Trust

    Manchester, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.